company background image
YSPS

Y.S.P. Southeast Asia Holding Berhad KLSE:YSPSAH Stock Report

Last Price

RM2.05

Market Cap

RM289.1m

7D

6.2%

1Y

3.5%

Updated

14 Aug, 2022

Data

Company Financials
YSPSAH fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance1/6
Financial Health5/6
Dividends5/6

YSPSAH Stock Overview

Y.S.P. Southeast Asia Holding Berhad, together with its subsidiaries, manufactures and sells pharmaceutical products.

Y.S.P. Southeast Asia Holding Berhad Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Y.S.P. Southeast Asia Holding Berhad
Historical stock prices
Current Share PriceRM2.05
52 Week HighRM2.39
52 Week LowRM1.88
Beta0.37
1 Month Change8.47%
3 Month Change5.13%
1 Year Change3.54%
3 Year Change-14.94%
5 Year Change-32.34%
Change since IPO14.41%

Recent News & Updates

Shareholder Returns

YSPSAHMY PharmaceuticalsMY Market
7D6.2%-0.2%0.2%
1Y3.5%-3.9%-3.5%

Return vs Industry: YSPSAH exceeded the MY Pharmaceuticals industry which returned -3.9% over the past year.

Return vs Market: YSPSAH exceeded the MY Market which returned -3.5% over the past year.

Price Volatility

Is YSPSAH's price volatile compared to industry and market?
YSPSAH volatility
YSPSAH Average Weekly Movement2.7%
Pharmaceuticals Industry Average Movement3.9%
Market Average Movement5.5%
10% most volatile stocks in MY Market11.7%
10% least volatile stocks in MY Market2.7%

Stable Share Price: YSPSAH is less volatile than 75% of MY stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: YSPSAH's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/aFang-Hsin Leehttps://www.yspsah.com

Y.S.P. Southeast Asia Holding Berhad, together with its subsidiaries, manufactures and sells pharmaceutical products. The company operates in three segments: Manufacturing, Trading, and Investment Holding. It manufactures, sells, trades in, and distributes pharmaceutical and veterinary products, pharmaceutical fine chemicals, raw material, health food products, and medical devices.

Y.S.P. Southeast Asia Holding Berhad Fundamentals Summary

How do Y.S.P. Southeast Asia Holding Berhad's earnings and revenue compare to its market cap?
YSPSAH fundamental statistics
Market CapRM289.08m
Earnings (TTM)RM18.90m
Revenue (TTM)RM292.20m

15.3x

P/E Ratio

1.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
YSPSAH income statement (TTM)
RevenueRM292.20m
Cost of RevenueRM174.45m
Gross ProfitRM117.74m
Other ExpensesRM98.84m
EarningsRM18.90m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.13
Gross Margin40.30%
Net Profit Margin6.47%
Debt/Equity Ratio9.9%

How did YSPSAH perform over the long term?

See historical performance and comparison

Dividends

3.9%

Current Dividend Yield

52%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is YSPSAH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YSPSAH?

Other financial metrics that can be useful for relative valuation.

YSPSAH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.7x
Enterprise Value/EBITDA5.3x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does YSPSAH's PE Ratio compare to its peers?

YSPSAH PE Ratio vs Peers
The above table shows the PE ratio for YSPSAH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average16.3x
KOTRA Kotra Industries Berhad
10.4xn/aRM605.2m
RHONEMA Rhone Ma Holdings Berhad
13x-3.7%RM152.6m
DPHARMA Duopharma Biotech Berhad
18.9x7.8%RM1.3b
AHEALTH Apex Healthcare Berhad
23x5.8%RM1.5b
YSPSAH Y.S.P. Southeast Asia Holding Berhad
15.3xn/aRM289.1m

Price-To-Earnings vs Peers: YSPSAH is good value based on its Price-To-Earnings Ratio (15.3x) compared to the peer average (16.3x).


Price to Earnings Ratio vs Industry

How does YSPSAH's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

Price-To-Earnings vs Industry: YSPSAH is expensive based on its Price-To-Earnings Ratio (15.3x) compared to the MY Pharmaceuticals industry average (14.2x)


Price to Earnings Ratio vs Fair Ratio

What is YSPSAH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YSPSAH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate YSPSAH's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of YSPSAH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: YSPSAH (MYR2.05) is trading below our estimate of fair value (MYR17.22)

Significantly Below Fair Value: YSPSAH is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Y.S.P. Southeast Asia Holding Berhad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Y.S.P. Southeast Asia Holding Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Y.S.P. Southeast Asia Holding Berhad is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.

Past Performance

How has Y.S.P. Southeast Asia Holding Berhad performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-10.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: YSPSAH has high quality earnings.

Growing Profit Margin: YSPSAH's current net profit margins (6.5%) are lower than last year (6.6%).


Past Earnings Growth Analysis

Earnings Trend: YSPSAH's earnings have declined by 10% per year over the past 5 years.

Accelerating Growth: YSPSAH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: YSPSAH had negative earnings growth (-0.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (21.4%).


Return on Equity

High ROE: YSPSAH's Return on Equity (5.3%) is considered low.


Discover strong past performing companies

Financial Health

How is Y.S.P. Southeast Asia Holding Berhad's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: YSPSAH's short term assets (MYR320.1M) exceed its short term liabilities (MYR66.4M).

Long Term Liabilities: YSPSAH's short term assets (MYR320.1M) exceed its long term liabilities (MYR34.0M).


Debt to Equity History and Analysis

Debt Level: YSPSAH has more cash than its total debt.

Reducing Debt: YSPSAH's debt to equity ratio has increased from 5.2% to 9.9% over the past 5 years.

Debt Coverage: YSPSAH's debt is well covered by operating cash flow (169.5%).

Interest Coverage: YSPSAH's interest payments on its debt are well covered by EBIT (26.1x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Y.S.P. Southeast Asia Holding Berhad current dividend yield, its reliability and sustainability?

Dividend Score

5/6

Dividend Score 5/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


3.90%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: YSPSAH's dividend (3.9%) is higher than the bottom 25% of dividend payers in the MY market (2%).

High Dividend: YSPSAH's dividend (3.9%) is low compared to the top 25% of dividend payers in the MY market (4.87%).


Stability and Growth of Payments

Stable Dividend: YSPSAH's dividends per share have been stable in the past 10 years.

Growing Dividend: YSPSAH's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (52.3%), YSPSAH's dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (18.7%), YSPSAH's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

15.6yrs

Average management tenure


CEO

Fang-Hsin Lee (62 yo)

18.75yrs

Tenure

RM86,000

Compensation

Dr. Fang-Hsin Lee serves as Director of Yung Shin Pharm. Ind. Co., Ltd.He serves as a Director at Vetnostrum Animal Health Co., Ltd. He serves as Supervisor of Chemix Inc. since March 18, 2022. He has bee...


Leadership Team

Experienced Management: YSPSAH's management team is seasoned and experienced (15.6 years average tenure).


Board Members

Experienced Board: YSPSAH's board of directors are seasoned and experienced ( 17 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Y.S.P. Southeast Asia Holding Berhad's employee growth, exchange listings and data sources


Key Information

  • Name: Y.S.P. Southeast Asia Holding Berhad
  • Ticker: YSPSAH
  • Exchange: KLSE
  • Founded: 1987
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: RM289.077m
  • Shares outstanding: 141.01m
  • Website: https://www.yspsah.com

Location

  • Y.S.P. Southeast Asia Holding Berhad
  • Menara LGB
  • Level 22
  • Kuala Lumpur
  • Wilayah Persekutuan
  • 60000
  • Malaysia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/14 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.